Reliant Technologies Inc.
Division of Bausch Health Companies Inc.
Latest From Reliant Technologies Inc.
The market for aesthetic laser technology has been growing in the past few years, as the public searches for the perfect combination of low-priced, minimally invasive treatments that promise to restore a more youthful appearance. Dermatologists are the key medical practitioners in this field, and although many physicians have been happy to add new, revenue-producing therapies, the lack of extensive clinical data - particularly in the area of laser-liposuction - is a source of concern for a number of doctors.
Investors love to remind everyone that IPOs are financing events, not exiting events, using the mantra to put off Judgment Day for their investments. So how have device companies fared after the recent spate of IPOs?
As 2008 draws to a close, In Vivo takes stock of the major events affecting the medical device industry in 2008. Two stories continue to unfold; how the new Obama administration will control national health spending, and the financial crisis that hit the US and global economies. The latter is already taking its toll on medtech. Financial markets crashed, and so did public device companies. M&A dwindled as the year went on, with some notable--and surprising--exceptions, and the downturn is driving VCs to invest either extremely early or late. In other stories: the Department of Justice continued probing into physician conflict of interest matters, this time focusing on the influential Cardiovascular Research Foundation. Also from Washington, the 510(k) process is under review, and 2009 may see changes that make the process of demonstrating safety and effectiveness more costly for device companies. CMS instituted payment reforms affecting hospitals, although this may be good news for medtech companies offering products to help curb hospital-acquired infections and medical errors. The news was good in diabetes--for devices, not pharmaceuticals--with positive outcomes from a major trial on continuous glucose monitoring and two new markets opening up in diabetes for device manufacturers. The regulatory agency delivered some positive news to companies in cardiac rhythm management and neurostimulation too. And second generation drug-eluting stents found a market more receptive than it was a year ago.
The depressed economy has hit all medtech stocks, but some harder than others, in particular, those that rely on nervous consumers to pay out of pocket for elective procedures, namely, medical aesthetics, and refractive surgery. J&J was thus able to acquired breast-implant manufacturer Mentor for much less than it would have had to pay a year ago, when it was first rumored to be looking to get into the aesthetics market.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Bausch Health Companies Inc.
- Senior Management
Eric B Stang, Pres. & CEO
Andrew Galligan, CFO
Keith J Sullivan, VP, Sales
- Contact Info
Reliant Technologies Inc.
Phone: (888) 437-2935
464 Ellis St.
Mountain View, CA 94043
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.